Search Medical Condition
San Gabriel, California Clinical Trials
A listing of San Gabriel, California clinical trials actively recruiting patient volunteers.
Found (572) clinical trials
Vortioxetine 5 10 and 20 mg Relapse Prevention Study in Adults With Major Depressive Disorder
The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine. The study will ...
0.77 miles
Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects
This study will consist of three study periods as follows: Screening Period of up to 6 weeks (8 weeks if on Mircera) Treatment Period: a minimum of 52 weeks, a maximum of up to 3 years. A Follow-up period of 4 weeks. A total of up to 820 patients will ...
0.77 miles
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
The goal of this study is to further develop a non-invasive prenatal blood test that can diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in the mother's bloodstream during pregnancy. Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or extra pieces of DNA ...
0.77 miles
Open-Label Extension and Safety Study of Talazoparib
This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.
1.38 miles
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) ...
1.38 miles
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
At the end of the study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study. The decision to allow the patient to continue dosing with talazoparib ...
1.38 miles
A Study of Apixaban in Patients With Atrial Fibrillation Not Caused by a Heart Valve Problem Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Patients will be recruited from either inpatient coronary care or general medical units, or recruited from outpatient cardiology offices. Masking Apixaban: Open label. VKA: Open label. Acetylsalicylic acid film coated tablet: Double Blinded. Placebo matching Acetylsalicylic acid film coated tablet: Double Blinded.
1.38 miles
MultiPoint Pacing Post Market Study
Any patient who received a market approved SJM Quadra Allure MP, Quadra Assura MP, or newer SJM CRT MP device is eligible for enrollment in the study. MultiPoint Pacing (MPP) programming guidance will be specified in the protocol. Patients will be followed for 12 months after implant. Data will be ...
1.38 miles
MILD Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Using the Centers for Medicare and Medicaid (CMS) Medicare Research Identifiable Files (RIFs) containing all medical claims for 100% of Medicare beneficiaries enrolled in the Medicare fee-for-service program, claims-based patient history and demographics will be combined with longitudinal analyses. In this study, the control group will include all patients receiving ...
1.38 miles
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
This study includes an Open-Label and a Double-Blind component. In each, there is an up to 28 days screen period followed by a treatment period of 52 weeks and a 4 week end of treatment assessment.
1.38 miles